Find trials
Consejos para buscar

Ultrasound Microvessel Imaging for Differentiation of Ocular Tumors

Overview

Información sobre este estudio

The purpose of ths study is to evaluate a contrast-free ultrasound tool for the visualization and quantification of tumor microvessel morphologies, called quantitative high-definition microvessel imaging (qHDMI). This technology includes three components: (1) novel processing procedures to reveal small microvasculatures using high frame rate ultrasound imaging; (2) quantification procedures to analyze the morphology of the microvasculatures in terms of 10 parameters (e.g., tortuosity, branch angle, number of branch points, etc.); and (3) a classification method to automatically determine if the lesion is benign or malignant based on its morphological signature. 

The proposed technique is noninvasive, affordable, portable, and utilizes tools without the risks and adverse effects inherent to the use of contrast agents. This project includes several novelties, including the innovative approach to differentiate benign versus malignant ocular tumors without using contrast agents, quantitative assessment of microvessel morphology for automated classification of the ocular tumor, and the first application of the proposed approach in a clinical study on patients with ocular/orbital tumors.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Male and female, age 18 and older.
  • Suspected of having eye tumor.

AIM 1 - SUBSET OF LARGE CHOROIDAL NEVI:

Inclusion Criteria:

  • Lesions with thickness > 1.5 mm and minimum documented stability interval of 2 years.

Exclusion Criteria:

  • Lesions with thickness < 1.5 mm or fewer than 2 years of documented stability.

SUBSET LARGE MELANOMA:

Inclusion Criteria:

  • Choroidal, ciliary body, or ciliochoroidal melanoma in a patient who elected to have enucleation for primary tumor treatment.

Exclusion Criteria:

  • Iris melanoma or melanoma that has undergone prior treatment before enucleation.

PRESUMED CHOROIDAL MELANOMA:

Inclusion Criteria:

  •  Choroidal, ciliary body, or ciliochoroidal melanoma with thickness > 1.5 mm treated by radiation. These lesions may sometimes have biopsy for cytogenetic testing at the time of radiation treatment.

Exclusion Criteria:

  • Iris melanoma, lesions with thickness < 1.5 mm, non-melanoma tumors.

AIM 2

Inclusion Criteria:

  • Orbital mass with completed neuroimaging (typically with MRI) and clinical/MRI suspicion for lymphoma.

Exclusion Criteria:

  • Recent orbital biopsy (within the past 3 months) prior to qHDMI, clinical impression clearly compatible with a non-lymphoma tumor type.

Eligibility last updated 2/18/22. Questions regarding updates should be directed to the study team contact.

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Azra Alizad, M.D.

Cerrado; inscripción por invitación

¿Qué es esto? (?)
"Close"
El estudio no está abierto para todos los que cumplen con los criterios de elegibilidad, sino solamente para las personas que el equipo del estudio ha invitado a participar.

Contact information:

Azra Alizad M.D.

(507) 538-1727

Alizad.Azra@mayo.edu

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20540954

Mayo Clinic Footer